ASBP
Aspire Biopharma Holdings, Inc.
Next earnings ≈ Aug 14, 2026 · est. from filing cadence
$6.00
▼ -7.05%$6.00▼ -47.37%
over 1Y
L $0.19EODHDH $702.96
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-7.0%
1W-7.0%
1M+28.5%
3M-78.1%
YTD-96.3%
1Y-47.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Conservative balance sheet (liabilities/equity -1.21x); but unprofitable (net margin -394725.1%).
Revenue (FY2025) $6.20K · FY2025
Aspire Biopharma Holdings, Inc. shows $6.20K in FY2025 revenue, a -394725.1% net margin.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | — | — | — | $6.20K |
| Gross profit | — | — | — | -$116.00 |
| Operating income | — | — | -$1.21M | -$19.4M |
| Net income | $3.34M | $4.46M | -$1.31M | -$24.5M |
| Diluted EPS | — | — | -$1.90 | -$16.38 |
| Net margin | — | — | — | -394725.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$29.1M
EV / EBITDA—
EV / Sales4698.6
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-81.2%
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash$1.00M
Altman Z-Score-81.14 distress
Piotroski F-Score3/6
Capital returns
Buyback yield45.7%
Dividend yield (est.)—
Shareholder yield45.7%
Shares Δ YoY-89.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-162026-06-22open ↗8-KPeriod ending 2026-06-092026-06-12open ↗8-KPeriod ending 2026-06-122026-06-12open ↗10-QPeriod ending 2026-03-312026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗8-KPeriod ending 2026-05-112026-05-14open ↗SCHEDULE 13G/AFiling2026-05-13open ↗DEFR14AFiling2026-05-12open ↗DEF 14APeriod ending 2026-05-082026-05-08open ↗PRE 14APeriod ending 2026-04-272026-04-27open ↗8-KPeriod ending 2026-04-202026-04-20open ↗8-K/APeriod ending 2026-04-152026-04-17open ↗
Frequently asked
- Is Aspire Biopharma Holdings, Inc. (ASBP) a buy?
- ASBP currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.21x); but unprofitable (net margin -394725.1%).
- What is Aspire Biopharma Holdings, Inc.'s quality score?
- ASBP scores 18.941176470588236/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001847345, latest 10-Q filed 2026-05-15) · EODHD · as of 6/26/2026, 2:08:42 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.